TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01989936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Description: Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Description: Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
Study: NCT00218452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
Study: NCT01879891

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic
Description: Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic
Description: Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
Study: NCT00242944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: Pitavastatin 4mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20mg per day
Study: NCT00397449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)
Study: NCT01008436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omni-stat Celox
Description: Topical administration of 6 gr of Omnistat Celox
Study: NCT01787396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(Metformin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(Gemigliptin)
Study: NCT01566149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI
Description: Two oral inhalations per dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI
Description: Two oral inhalations per dose
Study: NCT03172754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Tyrosine kinase inhibitor
Study: NCT01008436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Traditional surgical Hemostasis
Study: NCT01426009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 via nebulizer (eFlow®) 25 ug
Description: EP-101 (25 ug ) Dose 1 administered once daily for 7 days
Study: NCT03172754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Tyrosine kinase inhibitor
Study: NCT01426009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 via nebulizer (eFlow®) 50 ug
Description: EP-101 (50 ug ) administered once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 via nebulizer (eFlow®) 100 ug
Description: EP-101 (100ug) administered once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EP-101
Description: Placebo EP-101 administered once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide via (Spiriva® Handihaler®)
Description: Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium bromide Inhalation Solution via Handihaler® DPI
Description: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 via nebulizer (eFlow®) 200 ug
Description: EP-101 (200) ug administered once daily for 7 days
Study: NCT00965744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vessel sealing system LigaSure
Description: Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
Study: NCT01938391

Intervention type: DEVICE
Group type: OTHER
Intervention: Stealth 360°® OAS
Description: Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
Study: NCT00542373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo oral tissue collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Microscopy
Description: Mouth tissue examined microscopically for cytologic features

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Procedure
Description: Undergo standard white light headlamp oral examination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo widefield fluorescent and reflectance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Spectroscopy
Description: Undergo point fluorescent spectroscopy
Study: NCT03267433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo HCT
Study: NCT06002997

Intervention type: OTHER
Intervention: Pregnancy and/or delivery complications
Description: Analysis of post-delivery reports for pregnancy and/or delivery complications.

Intervention type: OTHER
Intervention: Pregnancy and/or delivery complications
Description: Analysis of post-delivery reports for pregnancy and/or delivery complications.

Intervention type: OTHER
Intervention: Periodontal disease
Description: Measuring clinical periodontal parameters for assessing presence of periodontal disease.

Intervention type: OTHER
Intervention: Periodontal disease
Description: Measuring clinical periodontal parameters for assessing presence of periodontal disease.
Study: NCT03267433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT02875366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Study: NCT02311452

Intervention type: DEVICE
Intervention: Peripherally Inserted Central Catheter (PICC)
Description: Post-discharge antibiotics delivered via a PICC line.

Intervention type: DEVICE
Intervention: Peripherally Inserted Central Catheter (PICC)
Description: Post-discharge antibiotics delivered via a PICC line.
Study: NCT02875366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03184766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
Study: NCT05088798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoro Dopa PET/MRI Imaging
Description: The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
Study: NCT00587275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: Oral, sachet, 2 grams daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celphere CP-305
Description: Oral, sachet, 2 grams daily for 4 weeks
Study: NCT04255212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue treatment
Description: Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mechaninsms explanation
Description: Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
Study: NCT03184766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules
Description: 2 x 200 mg solubilised ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules
Description: 2 x 200 mg solubilised ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules
Description: 2 x 200 mg solubilised ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules
Description: 2 x 200 mg solubilised ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules
Description: 2 x 200 mg solubilised ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules
Description: 2 x 200 mg solubilised ibuprofen
Study: NCT03750344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
Study: NCT01341925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Supplementation
Description: The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Supplementation
Description: The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Psychotherapy (PEP)
Description: Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Psychotherapy (PEP)
Description: Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
Study: NCT05084820

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Action observation treatment
Description: Participants will watch 5 videos of motor tasks; each video is of 30 sec and watch for 4 times (i.e. for 2 minutes). Then patient will execute the motor act, soon after the observation with an affected limb for 2 minutes, with total rest time of 5 minutes for this treatment. Conventional treatment of muscle stretching, strengthening and ROM exercises will be given for 15 minutes including rest. Total treatment time is 40 minutes.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: conventional treatment of 40 minutes in total will be performed including Stretching (for 8-10 sec with set of 5 repetitions/ session on each side for 3 minutes total with rest), strengthening (weighted bicep curls, side arm raise and open arm movement exercises with set of 5 repetitions/ session for 9 minutes total with rest), Range of motion exercises active and passive with set of 5 repetitions/ session for 3 minutes total with rest and gripping,reaching, grasping exercises (on each side for total 25 minutes including rest) with assistance of physiotherapist
Study: NCT01476553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive Intraperitoneal Lavage (EIPL)
Description: EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius).
Study: NCT04942769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: selenium 100ug ，take it orally twice daily
Study: NCT01983683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Cadazolid 250 mg as oral suspension twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 125 mg as oral capsules 4 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cadazolid-matching placebo
Description: Placebo matching cadazolid and administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin-matching placebo
Description: Placebo capsules matching vancomycin and administered orally 4 times per day
Study: NCT03267433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow biopsy and aspirate
Study: NCT03414268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micronized dHACM
Description: 1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Injection of 1mL 0.9% Sodium Chloride Injection, USP
Study: NCT04282369

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHHFNC
Description: noninvasive ventilation modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: noninvasive ventilation modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: noninvasive ventilation modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NHFO
Description: noninvasive ventilation modality
Study: NCT01846208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egg Oral Immunotherapy
Description: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egg Oral Immunotherapy
Description: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baked Egg
Description: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
Study: NCT03729908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal assisted mindfulness based intervention
Description: A mindfulness based intervention in the presence of an animal

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-stress program
Description: A mindfulness based intervention with no reference to animals
Study: NCT03267433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow biopsy and aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspirate